315 related articles for article (PubMed ID: 22145392)
1. [Statins in primary prophylaxis of cardiovascular diseases].
Kobalava ZhD; Villeval'de SV
Ter Arkh; 2011; 83(9):70-5. PubMed ID: 22145392
[TBL] [Abstract][Full Text] [Related]
2. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
Albert MA; Glynn RJ; Fonseca FA; Lorenzatti AJ; Ferdinand KC; MacFadyen JG; Ridker PM
Am Heart J; 2011 Jul; 162(1):106-14.e2. PubMed ID: 21742096
[TBL] [Abstract][Full Text] [Related]
3. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
4. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].
Olsson AG
Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435
[No Abstract] [Full Text] [Related]
5. The gravity of JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin).
O'Keefe JH; Carter MD; Lavie CJ; Bell DS
Postgrad Med; 2009 May; 121(3):113-8. PubMed ID: 19491548
[TBL] [Abstract][Full Text] [Related]
6. Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
Wells MT; Eisenberg T
Circulation; 2010 Dec; 122(23):e575; author reply e577. PubMed ID: 21135368
[No Abstract] [Full Text] [Related]
7. Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
Vos E; Rose CP; Biron P
Circulation; 2010 Dec; 122(23):e576; author reply e577. PubMed ID: 21135369
[No Abstract] [Full Text] [Related]
8. The numbers are in: statins for the primary prevention of cardiovascular disease in women.
Duvernoy CS; Blumenthal R
Circulation; 2010 Mar; 121(9):1063-5. PubMed ID: 20176993
[No Abstract] [Full Text] [Related]
9. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.
de Lorgeril M; Salen P; Abramson J; Dodin S; Hamazaki T; Kostucki W; Okuyama H; Pavy B; Rabaeus M
Arch Intern Med; 2010 Jun; 170(12):1032-6. PubMed ID: 20585068
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
Ohsfeldt RL; Olsson AG; Jensen MM; Gandhi SK; Paulsson T
J Med Econ; 2012; 15(1):125-33. PubMed ID: 22050473
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
Hsia J; MacFadyen JG; Monyak J; Ridker PM
J Am Coll Cardiol; 2011 Apr; 57(16):1666-75. PubMed ID: 21492764
[TBL] [Abstract][Full Text] [Related]
12. [JUPITER no support of changed guidelines for cardiovascular prevention. Moderate absolute risk reduction and uncertain long term effects].
Håkansson J
Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1460-1. PubMed ID: 19579433
[No Abstract] [Full Text] [Related]
13. Rosuvastatin and the JUPITER trial: critical appraisal of a lifeless planet in the galaxy of primary prevention.
López A; Wright JM
Int J Occup Environ Health; 2012; 18(1):70-8. PubMed ID: 22550699
[TBL] [Abstract][Full Text] [Related]
14. Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
Cardiovasc J Afr; 2008; 19(6):332-4, discussion 335. PubMed ID: 19104734
[No Abstract] [Full Text] [Related]
15. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
16. The JUPITER trial: How will it change clinical practice?
Watson KE
Rev Cardiovasc Med; 2009; 10(2):91-6. PubMed ID: 19593321
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study.
Michos ED; Blumenthal RS
J Am Coll Cardiol; 2009 Mar; 53(11):931-5. PubMed ID: 19281922
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of rosuvastatin therapy JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Hlatky M
J Am Coll Cardiol; 2011 Feb; 57(7):792-3. PubMed ID: 21310314
[No Abstract] [Full Text] [Related]
19. The editor's roundtable: the JUPITER trial--initial results and clinical implications.
Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC
Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439
[No Abstract] [Full Text] [Related]
20. Another look at the results of the JUPITER trial.
Kappagoda CT; Amsterdam EA
Am J Cardiol; 2009 Dec; 104(11):1603-5. PubMed ID: 19932800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
